Manufacturing Systems, Single-Use

Fujifilm is expanding its R&D footprint at its California facility.

Disposable equipment components find use in small-volume aseptic biopharmaceutical manufacturing.

Large-scale single-use bioreactors prove successful as limits are tested.

Early control architecture decisions can impact a facility’s long-term growth, flexibility, and efficiency.

CPC’s MicroCNX Series Connectors provide an alternative to tube welding at small tubing sizes.

Thermo Fisher Scientific plans to expand its Nashville, Tenn., site by establishing a dedicated single-use technology manufacturing facility at the site, doubling capacity.

The benefits of single-use technologies for upstream viral-vector processes clearly outweigh their disadvantages.

Through the adoption of single-use technology, drug manufacturers have been able to adapt to the challenges posed by the COVID-19 pandemic.

NewAge Industries is adding cleanrooms at its Pennsylvania headquarters.

Through the acquisition, Avantor will have access to RIM’s Changzhou, China, facility, making it Avantor’s first single-use production plant in the AMEA region.

Lonza plans to invest approximately CHF 850 million (US$936 million) to build new state-of-the-art mammalian manufacturing facilities at its Visp, Switzerland, and Portsmouth, NH, sites.

Avantor plans to increase its single-use manufacturing footprint by 30% and double its cleanroom space in the US and Europe.

AkesoBio’s expanded manufacturing capacity, enabled by the addition of another Cytiva FlexFactory platform, will be used to meet current and future market needs in China as well as worldwide.

Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics for upstream bioprocessing capacity.

The innovation of single-use technologies is applicable early on in the manufacturing process.

The adoption of single-use technologies in fluid-handling systems helps streamline downstream bioprocessing operations.

The availability of materials is a critical factor when it comes to vaccine capacity.

The investments are expected to double Thermo Fisher’s manufacturing capacity while creating more than 1500 jobs at 11 manufacturing sites in the Americas, Europe, and Asia.

Cytiva’s new facility in Shrewsbury, MA will make equipment such as single-use bioreactors.

Cytiva is adding process development, media and assay development, and contract development services at its facilities in Korea, Japan, Sweden, and the UK.

Set to be operational by the first quarter of 2022, the 140,000-ft2 facility will feature up to six 2000-L, single-use bioreactor systems along with additional harvest and purification equipment to produce up to 100 commercial batches annually.

Biopharma can apply new manufacturing practices adopted during the COVID-19 pandemic to enhance bioprocessing.

The latest advances in downstream technologies include sterile disconnects for single-use manufacturing systems, ligand technologies for purifying RNA and for COVID-19 vaccines, and an automated perfusion system.

The new facility at the company’s San Diego, CA, site will be for late phase and commercial CGMP manufacturing.

The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.